Dr. Xi (Hill) Liu earned his B.S. and M.S. degrees in chemistry and organic chemistry, respectively, from Zhejiang University. He later received is Ph.D. in pharmacology and toxicology from Dartmouth Medical School, where he was mentored by Dr. Ethan Dmitrovsky. Dr. Liu conducted a postdoctoral fellowship at the National Cancer Institute under Dr. Douglas Lowy. He joined the Department of Thoracic and Head & Neck Medical Oncology, MD Anderson Cancer Center as an instructor. In 2018, he co-established and currently oversees the Molecular Pharmacology Program at the Frederick National Laboratory, focusing on basic, translational and clinical lung cancer research.
Dr. Liu’s work integrates pre-clinical pharmacology, toxicology, immune oncology, and clinical studies, uncovering novel therapeutic mechanisms and targets. His team has contributed significantly to the understanding of CDK2 inhibitors, USP18 pathways, and combination therapies. Dr. Liu has received multiple awards, including the Norman P. Salzman Mentoring Award and the NCI Director's Intramural Innovation Award.
